Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ZOL-Treated Patients Showed a<br />
Nonsignificant Trend Toward Improved OS<br />
Overall survival, %<br />
100<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
No. of Hazard ratio (95% CI)<br />
events vs No ZOL P value<br />
ZOL 16 0.595 (0.32, 1.11) .101<br />
No ZOL 26<br />
0 12 24 36 48 60 72 84<br />
Time since randomization, months<br />
No. at risk<br />
No ZOL 904 838 735 565 441 265 161 60<br />
ZOL 899 851 744 573 434 270 131 59<br />
Median follow-up = 48 months.<br />
OS = Overall survival; CI = Confidence interval; ZOL = Zoledronic acid.<br />
Update of <strong>Gnant</strong> M, et al. Presented at: ASCO 20<strong>08</strong>. Chicago, IL. Abstract LBA4.<br />
12
Change language